top of page

New treatment for advanced form of kidney cancer

The European Medicines Agency (EMA) has recommended extending the use of Opdivo (nivolumab) to include the treatment of adult patients with advanced renal cell carcinoma (a type of kidney cancer) who have received prior therapy.

Opdivo was first authorised in the European Union (EU) in June 2015 for the treatment of advanced melanoma (a type of skin cancer) and already had its use extended (in October 2015) to treatment of the advanced stages of a type of lung cancer, squamous non-small cell lung cancer (NSCLC).

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page